Literature DB >> 6501103

Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit.

A Assandri, B Ratti, T Cristina.   

Abstract

A study on the pharmacokinetics of rifapentine, a new long-lasting rifamycin, has been carried out in the rat, the mouse and the rabbit. The investigation was made using either radioactive or unlabelled rifapentine and both the total 14C and the unchanged compound were assayed. In the rat, the overall evidence obtained was: the oral absorption of rifapentine into central compartment, due to its poor water solubility, appears to be dose-dependent with a satisfactory oral absorption (84%) after a dose of 3 mg/kg, lower (65%) after 10 mg/kg; the antibiotic undergoes rapid liver uptake while it diffuses into the tissue compartment more slowly, with particular affinity for the adrenals, pancreas and kidneys; concentrations higher than in plasma were also measured in the lungs; elimination of rifapentine from the blood and tissue compartments suggests a non linear capacity-limited kinetics where the terminal elimination phase has monoexponential course. Terminal plasma half-life ranged between 14 and 18 hours; the compound is eliminated mainly via the bile with the feces (92% of dose). In mice rifapentine shows a kinetic profile resembling that obtained in rats, whereas in rabbits is metabolized and/or eliminated much more rapidly with a half-life of only 1.8 hours.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6501103     DOI: 10.7164/antibiotics.37.1066

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  12 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Charles A Peloquin; Andrew A Vernon; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

3.  Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.

Authors:  Todd J Zurlinden; Garrett J Eppers; Brad Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  Rifapentine is active in vitro and in vivo against Toxoplasma gondii.

Authors:  F G Araujo; A A Khan; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages.

Authors:  N Mor; B Simon; N Mezo; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.

Authors:  E Miyazaki; R E Chaisson; W R Bishai
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

Review 8.  Rifapentine.

Authors:  B Jarvis; H M Lamb
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

9.  Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

10.  Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.

Authors:  Kendra K Radtke; Jacqueline P Ernest; Nan Zhang; Nicole C Ammerman; Eric Nuermberger; Robert Belknap; Rosanna Boyd; Timothy R Sterling; Rada M Savic
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.